EUVIMEDEUVIMED entdecken
Crossref

Genetically engineered macrophages as living cell drug carriers for targeted cancer therapy

Pengbo Ning, Fuyu Du, Haotian Wang, Xiaocheng Gong, Yuqiong Xia, Xianghan Zhang, Hongzhang Deng, Ruili Zhang, Zhongliang Wang

Journal of Controlled Release · 2024-03 · 367 · 697-707

DOI: 10.1016/j.jconrel.2024.02.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2024-03. Verfasst von Pengbo Ning und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science and Technology, Xidian University, Xi'an, Shaanxi 710071, PR China; Engineering Research Center of Molecular & Neuroimaging, M…. Hauptthemen laut MEDLINE: Nanoparticles, Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Precise targeting is a major prerequisite for effective cancer therapy because it ensures a sufficient therapeutic dosage in tumors while minimizing off-target side effects. Herein, we report a live-macrophage-based therapeutic system for high-efficiency tumor therapy. As a proof of concept, anti-human epidermal growth factor receptor-2 (HER2) affibodies were genetically engineered onto the extracellular membrane of macrophages (AE-Mφ), which further internalized doxorubicin (DOX)-loaded poly(lactic-co-glycolic acid) nanoparticles (NPs) to produce a macrophage-based therapeutic system armed with anti-HER2 affibodies. NPs(DOX)@AE-Mφ were able to target HER2+ cancer cells and specifically elicit affibody-mediated cell therapy. Most importantly, the superior HER2 + -targeting capability of NPs(DOX)@AE-Mφ greatly guaranteed high accumulation at the tumor site for improved chemotherapy, which acted synergistically with cell therapy to significantly enhance anti-tumor efficacy. This study suggests that NPs(DOX)@AE-Mφ could be utilized as an innovative 'living targeted drug' platform for combining both macrophage-mediated cell therapy and targeted chemotherapy for the individualized treatment of solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesNeoplasmsHumansDrug CarriersDrug Delivery SystemsDoxorubicinMacrophagesCell Line, Tumor

Stichwörter der Autor:innen

Engineering macrophagesHER2Nano deliverySolid tumorTargeting therapy

Substanzen

Drug CarriersDoxorubicin

Autor:innen und Institutionen

  • School of Life Science and Technology, Xidian University, Xi'an, Shaanxi 710071, PR China; Engineering Research Center of Molecular & Neuroimaging, Ministry of Education, Xi'an, Shaanxi 710071, PR China. Electronic addr…
  • School of Life Science and Technology, Xidian University, Xi'an, Shaanxi 710071, PR China; Engineering Research Center of Molecular & Neuroimaging, Ministry of Education, Xi'an, Shaanxi 710071, PR China.
  • Department of radiology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110801, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Ning, P., Du, F., Wang, H., Gong, X., Xia, Y., Zhang, X., Deng, H., Zhang, R., & Wang, Z. (2024). Genetically engineered macrophages as living cell drug carriers for targeted cancer therapy. Journal of Controlled Release, 367, 697-707. https://doi.org/10.1016/j.jconrel.2024.02.003

Vancouver

Ning P, Du F, Wang H, Gong X, Xia Y, Zhang X, et al. Genetically engineered macrophages as living cell drug carriers for targeted cancer therapy. Journal of Controlled Release. 2024;367:697-707. doi:10.1016/j.jconrel.2024.02.003

BibTeX
@article{Ning2024,
  author = {Ning, Pengbo and Du, Fuyu and Wang, Haotian and Gong, Xiaocheng and Xia, Yuqiong and Zhang, Xianghan and Deng, Hongzhang and Zhang, Ruili and Wang, Zhongliang},
  title = {Genetically engineered macrophages as living cell drug carriers for targeted cancer therapy},
  journal = {Journal of Controlled Release},
  year = {2024},
  volume = {367},
  pages = {697--707},
  doi = {10.1016/j.jconrel.2024.02.003}
}
Kostenlos starten →